Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.

ᅟ.

Correction to: BMC Cancer (2018) 18:1198

DOI: 10.1186/s12885-018-5110-2

Following publication of the original article [1], the authors notified us of a typographical error in Table 1.

Table 1

Patient Baseline Characteristics. The baseline demographics and clinical characteristics of patients with advanced EGFRm + NSCLC treated with first-line afatinib (n = 125) in our cohort

Characteristic	No.	%
Sex
Male	64	51.2
Female	61	48.8
Age at diagnosis, years
Median	62
Range	26–86
Ethnicity
Chinese	100	80.0
Malay	14	11.2
Indian	3	2.4
Others	8	6.4
Smoking status
Never	95	76.0
Former	17	13.6
Current	13	10.4
Histotype – NSCLC
Adenocarcinoma	121	96.8
Adenosquamous carcinoma	1	0.8
NOS	3	2.4
EGFR mutation type
Exon 19 deletion[a]	87	69.6
Exon 21 L858R	27	21.6
Others[b]	11	8.8
Brain metastases at baseline
No	82	65.6
Yes	42	33.6
Unknown	1	0.8
Starting dose of afatinib once daily (OD)
40 mg	62	49.6
30 mg	61	48.8
20 mg	1	0.8
Unknown	1	0.8

aE746_A750del; E746_A750delinsIP; E746_A750delinsQP; E746_A750delinsVP; E746_T751delinsV; E746_S752delinsV; E746_P753delinsVS; L747_A750delinsP; L747_T751del; L747_P753delinsS; NOS

bE697Q; A763_Y764insFQEA; Double mutation; Unknown NSCLC Non-small cell lung cancer, NOS Not otherwise specified

The corrected Table 1 is presented below.